Novartis's Biosimilar Zessly Gets European Commission Nod
May 24 2018 - 2:31AM
Dow Jones News
By Euan Conley
Novartis (NOVN.EB) said Thursday that the European Commission
has approved its subsidiary Sandoz's infliximab biosimilar, Zessly,
for use in Europe.
The company said the biosimilar has been approved for use in all
indications of the reference medicine--the compound it is designed
to act like--including rheumatoid arthritis and Crohn's disease.
Biosimilars are medical formulations with properties similar to
drugs that have already been licensed.
"Biosimilars, such as Zessly, help to address a significant
unmet need for earlier patient access to biologic medicines and are
at the heart of our Sandoz commitment to improving and extending
lives," said Richard Francis, Sandoz's chief executive.
Zessly is the third biosimilar from Sandoz to gain approval from
the commission in the past 12 months, Novartis said.
Write to Euan Conley at euan.conley@dowjones.com
(END) Dow Jones Newswires
May 24, 2018 02:16 ET (06:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
